Evolution of cell & gene therapy in China: the case for universal CAR-T

JIE CHEN

CHIEF MEDICAL OFFICER, BIOHENG

Dr. Chen has over 15 years of experience as an oncology clinician and over 21 years of experience in the industry. Prior to joining Bioheng, Dr. Chen served as the Head of Medical Affairs and the Vice President at Takeda China, where he was responsible for supporting the launch and product cycle management of innovative products such as Adcetris ®, Entyvio ®, Vocinti ®, Takhzyro ®, Firazyr ®, Edarbi ® and myPKfit®. Additionally, he held executive positions in Medical Affairs at Bristol-Myers Squibb (BMS), Pfizer, and Sunway biotech.

He was a major contributor to the first NMPA approval for a lysing virus and was responsible for the pre-marketing and launch of several oncology products such as Sunitinib, Crizotinib, and Nabumetinib in China.

Dr. Chen holds an MD degree from the Army Medical University and has postdoctoral experience from Fudan University. He is currently a member of the CSCO Expert Committee on Tumor Bio-marker, the CSCO Expert Committee on Tumor Immunotherapy (IO), an Honorary Member of CACA Professional Committee on Oncology Drug Research, and the CSCO Expert Committee on Translational Medicine.

VIVIAN GU

HEAD OF CDR, CHINA CMO, NOVOTECH PPC

Dr. Gu has a degree in Clinical Medicine from Fudan University, also previously known as Shanghai Medical University. With 8 years of physician experience in the internal medicine department in tertiary care hospital, Dr. Gu continues to contribute to her field intensively.

Dr. Gu has substantial experience with over 20 years of working at companies such as BI, AZ, BMS in the clinical research department. Dr. Gu has also worked as the head of CO for MNC of various industries for 16 years. Prior to joining PPC, she was a Senior VP of a leading China biotech company and carries rich experience after managing clinical, medical & regulatory affairs. With her wealth of experience, she has a deep insight into R&D needs and pathways for China's local biotech.

In addition, Dr. Gu also holds abundant experience across all the therapeutic areas in the clinical trials industry i.e onco, non-onco, such as Lung cancer, Liver cancers etc., PD- CLTA4, EGFR-TKI etc.

KAI XUE

ASSOCIATE PROFESSOR, DEPARTMENT OF HEMATOLOGY, RUIJIN HOSPITAL, SHANGHAI CHINA

Dr. Xue gained his master's degree in Hematology from Shanghai Jiao Tong University and a doctor's degree in Oncology from Fudan University and has 17 years of experience in hematological oncology. He worked at Fudan University Shanghai Cancer Center from 2009 to 2018, and since 2019, he has worked in Shanghai Ruijin Hospital. In 2013-2014, he studied at Roswell Park Cancer Institute as a visiting scholar under the supervision of world-renowned lymphoma expert Myron Czucuman. Dr. Xue has led two multicenter clinical trials and participated in more than 40 Chinese/international trials in the field of hematological oncology.

Dr. Xue is currently a member of the Youth Committee of the Hematological Oncology Professional Committee, the Chinese Anti-Cancer Association, the Youth Committee of the Chinese Society of Clinical Oncology (CSCO), the Vice-Chairman of the Youth Committee,the Hematology Branch of the Shanghai Medical Association, and a member of the clinical research committee of antitumor drugs of the Shanghai Anti-Cancer association. He has published over 15 scientific papers and gave oral presentations at the 54th annual ASH meeting.

MODERATOR

ARSALAN ARIF

FOUNDER & PUBLISHER, ENDPOINTS NEWS

Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.